Investment Summary

Haleon PLC, the consumer health Business demerged from GSK in 2022, is now an established global category leader with an enviable portfolio of trusted brands across oral health, pain relief, vitamins and supplements, respiratory health, digestive health and therapeutic skin care. Since spinning out, the company has steadily delivered organic Revenue growth ahead of category averages, expanded gross margins, deleveraged the Balance Sheet and built a leaner, more focused operating model. The combination of strong Brand Equity, structural growth in self-care, geographic Diversification and a clear path to higher cash returns supports our positive view. We rate Haleon a Buy, viewing it as a high-quality compounding consumer healthcare investment with attractive defensive characteristics.

Business Overview

Haleon is the world's largest pure-play consumer healthcare company, headquartered in Weybridge, United Kingdom, with a dual primary listing on the London Stock Exchange and American depositary receipts on the New York Stock Exchange. The portfolio is organised around five strategic categories: Oral Health, led by Sensodyne, parodontax, Polident, Poligrip and Aquafresh; Pain Relief, anchored by Panadol, Voltaren, Advil and Fenbid; Vitamins, Minerals and Supplements, including Centrum, Caltrate and Emergen-C; Respiratory Health, including Theraflu, Robitussin, Otrivin and Contac; and Digestive Health and Therapeutics, with brands such as TUMS, Eno, Nexium 24HR and Citrucel.

Geographically, the business is balanced across North America, EMEA and Latin America, and Asia Pacific, with significant emerging market exposure that provides long-term Volume growth potential. Haleon's brands are typically category leaders or strong number twos in their primary markets, supported by deep clinical heritage, professional endorsement and decades of consumer trust.

Sector Backdrop

The global consumer healthcare market benefits from several structural forces. Ageing populations and rising incidence of chronic conditions are driving increased Demand for over-the-counter remedies, daily preventive supplements, oral care and digestive health products. The rise of self-care, encouraged by both governments looking to ease pressure on health systems and consumers seeking convenience, is steadily widening the addressable market for OTC brands. The growing role of E-commerce, particularly in markets like China, India and parts of Latin America, has improved category accessibility and brand visibility. At the same time, regulators are gradually opening more product switches from prescription-only to OTC status, expanding the available consumer healthcare opportunity. These dynamics are favourable to global category leaders with the brand equity, scale and innovation capability to compete effectively, characteristics that play directly to Haleon's strengths.

Investment Thesis

Haleon represents a relatively rare investment proposition: a consumer staples-like business that combines defensive end-market demand with above-average organic growth potential. Several elements underpin the thesis. First, the company benefits from category-leading positions in markets that grow structurally at low to mid single-digit rates, with above-trend growth opportunities in emerging markets where category penetration remains low. Second, Haleon's brand portfolio is anchored by clinically differentiated, consumer-trusted franchises, with Sensodyne, Panadol, Voltaren and Centrum each generating substantial revenue and benefiting from significant pricing power. Third, the company is improving margins through procurement, Supply chain consolidation, network optimisation and rationalisation of its tail of smaller brands and SKUs. Fourth, Leverage is steadily reducing, opening the door to a faster pace of Capital return, including continued progressive Dividend growth and share Buybacks. Finally, Haleon's relative valuation now offers a more attractive entry point than at its IPO, with the multiple discount to consumer staples peers expected to narrow as the financial profile matures.

Growth Drivers

Several specific growth drivers reinforce the medium-term outlook. Sensodyne remains the global leader in sensitivity oral care and continues to benefit from premiumisation, new platform launches across whitening, complete care and gum health, and growing penetration in emerging markets where dental sensitivity is increasingly diagnosed. parodontax is benefiting from the rising focus on gum health and is being expanded across additional geographies. Voltaren continues to grow strongly in topical pain relief and has further runway across multiple international markets. Panadol remains a global pain relief ICON with continuing strong demand. Centrum is the world's leading multivitamin brand and is benefiting from heightened consumer interest in immunity, longevity and personalised supplementation, supported by new launches across gummies, performance and women's health. Digestive health brands such as TUMS and Nexium 24HR continue to gain share in segments where consumers value brand trust and efficacy. Across all categories, Haleon is investing in Marketing, scientific endorsement and digital activation to maintain category Leadership.

Emerging markets represent a particularly important growth corridor. Categories such as oral health, multivitamins and respiratory care still have meaningfully lower per-capita consumption in China, India, Indonesia, Mexico and other key economies than in developed markets. Rising disposable incomes, growing pharmacy networks, expanding e-commerce platforms and increasing consumer awareness of self-care collectively support a sustained volume growth runway. Haleon is investing in local salesforces, regionally tailored innovation and culturally relevant marketing to capture this opportunity. Within developed markets, premium-priced segments such as advanced oral care, scientifically substantiated supplements and digital-enabled wellness platforms support price/mix improvement. Finally, the ongoing trend of switches from prescription to over-the-counter status across selected molecules in pain, gastrointestinal and respiratory categories provides incremental opportunity that pure consumer goods companies typically cannot capture.

Financial Performance

Since demerger, Haleon has delivered organic revenue growth in the mid single digits with consistent volume and price/mix contribution. Adjusted operating margins have continued to expand modestly each year as procurement savings, Manufacturing optimisation and rationalisation initiatives flow through. Free Cash Flow generation is strong, with high conversion of operating profit to cash. Net Debt has steadily reduced as the company prioritises balance sheet strength alongside investment in brand building and innovation. Currency translation can be material given the company's global footprint, but underlying performance remains robust. Management has guided to medium-term organic revenue growth in the 4 to 6 percent range, with adjusted operating profit growing ahead of revenue and adjusted Earnings-per-share/">Earnings Per Share supported by ongoing buybacks and disciplined capital management.

Brand and Innovation Outlook

Innovation in consumer healthcare is increasingly anchored in clinical credibility, sensory experience and digital connection with consumers. Haleon's innovation pipeline targets areas of meaningful unmet consumer need such as advanced gum care, sustained-release pain relief, personalised vitamins, sleep support, immunity and digital toothbrushes integrated with diagnostic features. The company also continues to invest in pharmacist and dental professional engagement, supporting brand recommendation at the point of purchase. Innovation execution is supported by category-led R&D centres and consumer insights platforms across major regions, ensuring that new launches respond to local needs while leveraging global capabilities. The combination of brand heritage, clinical evidence and innovation pace differentiates Haleon from many competitors in the broader consumer goods landscape.

Commercialisation and Geographic Reach

Geographic diversification is one of Haleon's most attractive features. North America generates a substantial share of revenues and is supported by strong oral health, pain relief, vitamins and digestive health brands. Europe, the Middle East, Africa and Latin America together form a large second region with deep historical presence and resilient consumer franchises. Asia Pacific is the highest growth region, with China, India, Southeast Asia and Australia offering long-term volume expansion across multiple categories. The breadth of channel exposure, from large retailers and pharmacies to e-commerce and specialty drug stores, helps the business navigate evolving shopper behaviour and currency cycles. Continued investment in digital commerce capabilities, supply chain resilience and direct distribution in emerging markets should help sustain Market Share gains.

Dividend and Capital Returns

Haleon adopted a clear capital allocation framework at demerger, prioritising investment in the brand portfolio, debt reduction and a progressive dividend. As leverage has come down, the company has announced multi-year share buyback programmes that complement its dividend distributions, signalling growing confidence in the cash generation profile. The dividend, while modest in Yield terms at first, is expected to grow steadily in line with earnings, with payout supported by high free cash flow conversion. Together, dividend growth and ongoing buybacks should make a meaningful contribution to Shareholder returns alongside underlying operational progress.

Valuation Perspective

Haleon trades at a valuation broadly in line with or modestly below other consumer staples leaders, despite its defensive demand profile and superior organic growth pace relative to several peers. On forward earnings, free cash flow yield and Enterprise value to EBITDA metrics, the stock offers attractive value compared to the broader consumer health and personal care universe. As leverage continues to fall, organic growth holds in the mid single digits and the company demonstrates consistent Margin progress, we expect the valuation gap to close. The combination of multiple expansion, earnings growth and capital returns should generate compounding total returns over a multi-year horizon.

Key Risks

Risks include exposure to private label competition in select categories, especially in mature markets where consumers may trade down during periods of economic pressure. Regulatory changes around OTC product reclassification, ingredient bans or labelling requirements could affect specific lines. Currency Volatility, particularly across emerging market currencies, can affect reported growth and margins. Ongoing litigation related to a historical heritage product remains a Tail risk, though provisions have been taken and management has signalled confidence in the legal position. Finally, integration of new digital and direct-to-consumer channels requires sustained investment and capability building.

Operational Excellence and Productivity

Haleon has been executing on a multi-year productivity programme designed to capture cost synergies that were not available within the pre-demerger structure. Initiatives include consolidating procurement under a global function, optimising the manufacturing footprint, deploying common digital platforms across markets, simplifying SKU portfolios and improving supply chain agility. Reinvestment of a portion of these savings into brand marketing and innovation is supporting category share gains, while the balance is contributing to margin expansion. The company has also been rolling out advanced analytics, revenue growth management and pricing tools to optimise category and country performance, raising the quality of decision making and accelerating the time to market for new launches. Cumulatively, these initiatives are expected to deliver meaningful margin uplift across the medium term while preserving brand investment intensity, a combination that we view as differentiating among large consumer healthcare players.

Sustainability and Stakeholder Strategy

Haleon has a clearly articulated sustainability strategy organised around three pillars: better everyday health with humanity, a healthier planet and a more inclusive company. The Better Everyday Health with Humanity pillar focuses on broadening access to consumer healthcare and reducing health inequities. The planetary pillar includes commitments to reduce greenhouse gas emissions across operations and the value chain, transition to recyclable or reusable packaging, reduce water use intensity and integrate sustainable design principles into innovation. The inclusive pillar covers workforce diversity, equity and inclusion and supplier diversity. These commitments not only support brand trust and consumer loyalty but increasingly Factor into retailer and regulatory expectations, particularly in Europe. Strong governance, transparent reporting and active engagement with investors round out a credible ESG positioning.

Conclusion: Why We Rate Haleon a Buy

Haleon offers investors a high-quality consumer healthcare investment combining defensive demand, category leadership, a global emerging markets growth angle and improving margins. Brands such as Sensodyne, Panadol, Voltaren and Centrum provide structural revenue resilience, while innovation, premiumisation and emerging markets penetration provide growth optionality. With leverage falling, free cash flow strong, and capital returns rising, the long-term compounding profile is attractive. We therefore assign Haleon PLC a Buy rating, viewing the shares as a core holding for investors seeking quality consumer healthcare exposure with defensive characteristics. The combination of organic growth, margin expansion, dividend growth and share buybacks should support attractive Risk-adjusted total returns for patient investors.